# Sprott Equity Research

20 September 2021

Ticker: BNKR US/CN	<b>2Q21 Cash:</b> C\$2.4m	Project: Bunker Hill	
Market cap: C\$34m	<b>Price:</b> C\$0.21/sh	Country: USA, Idaho	
RECOMMEND. (unc): BUY	TARGET (up): C\$0.70/sh	RISK RATING: HIGH	

Today's PEA update is simple in its shift to longhole from hybrid with cut-and-fill for a +38% after-tax NPV given higher productivity and lower unit costs. Long-holing typically risks higher dilution, but the average  $^{\circ}$ 6m wide stopes, combined with short  $^{\sim}$ 15m sub-levels, offsets this with less 'chance' for ore to move away from its expected location. Some additional dilution is incurred, but this is more than offset by the +38% lift in NPV resulting from 29% lower mining costs at \$41/t. Adjusting for this, we maintain our BUY rating and lift our PT from C\$0.60/sh to C\$0.70/sh based on 0.5xNAV<sub>7%</sub> of the PEA mine plan at 127c/lb Zn, 104c/lb Pb and US\$24/oz, net of option payments, holding resources outside inventory at 120c/oz AgEq. With US\$44m capex, we expect a ~US\$60-70m finance package, a key hurdle given the current cash and market cap. We see three opportunities to mitigate this; (i) we would like to think the EPA would accept rescheduled ~US\$15m trailing payments given BNKR backfill 'plugs' the source of AMD in the region (flooded open stopes, to be backfilled); (ii) as a polymetallic, streaming and offtake finance options bulk out debt flexibility, and (iii) if these are booked, we see a more liquid listing as achievable. None of these are a given, hence the ball is in management's court to do a financial 'clean up'. The added advantage of debt coming before equity is further de-risking of technical aspects given the build is proposed to be done from a PEA. That risk is offset by a long history of production, but a 'second set of eyes' on proposed mining method, resource conversion and UG plant would benefit equity holders in our view.

			•
Bunker Hill (100%)	June PEA	Sept PEA	∆ to old
UG inventory (Mt ore)	5.0	5.8	17%
Grade (% Zn)	5.5%	5.0%	-9%
Grade (% Pb)	2.9%	2.8%	-3%
Grade (g/t Ag)	52.2	51.4	-1%
Zinc mined (000t Zn)	274	289	6%
Lead mined (000t Pb)	144	162	13%
Silver mined (000oz)	7401	9568	29%
LOM avg ROM (Mt pa)	0.5	0.5	0%
Zn Recovery (LOM, %)	92%	92%	0%
Prod'n (000t pa ZnEq)	41	41	-1%
Mine life (years)	10	11	10%
Zinc price (US\$000/t)	2,535	2,535	0%
Lead price (US\$000/t)	1,984	1,984	0%
Silver price (US\$/oz)	20	20	0%

#### Table 1. Bunker Hill Mine previous 2Q21 PEA vs 3Q21 PEA update

Bunker Hill Mine (100%)	June PEA	Sept PEA	∆ to old
UG mining cost (US\$/t)^	58.0	41.0	-29%
Processing cost (US\$/t)^	15.0	15.0	0%
G&A cost (US\$/t ROM)^	6.0	6.0	0%
AISC (US\$/Ib Zn payable)	0.65	0.47	-28%
Initial capex (US\$m)	42.0	44.0	5%
LOM sust. capex (US\$m)	73.5	63.1	-14%
LOM FCF (US\$M)	196	278	41%
Discount rate (%)	8%	8%	0%
Project NPV (US\$m)	78.4	107.8	38%
Asset IRR (%)	46.0%	35.2%	-23%

Source: Bunker Hill, SCP

### Lifting our PT to C\$0.70/sh as updated PEA NPV improves +38% with shift to longhole mining

Today's PEA update lifts **after tax NPV<sub>8%</sub> from US\$78m (2Q21) to US\$108m** as mining method shifts to longhole from primarily cut & fill, diluting head grades slightly and adding 5% to upfront development costs but offset by reduced **mining costs** from US\$58/t to US\$41/t. **Sustaining capex** fell from US\$73m to US\$63m to drive a 28% reduction in US\$/lb Zn AISC costs. All else remains largely unchanged including the development / mining schedule and metal price assumptions.

### Valuation update: maintain our BUY rating and lift PT to 70c/sh from 60c/sh

We are updating our assumptions (Table 2) for the updated PEA: (i) updated mine plan / scheduled tonnes and grade, (ii) reduced operating and sustaining costs and lastly (iii) modest 5% lift in build capex for a +37% lift in after-tax NPV to US\$175m and 52% IRR (+7% lift) using our metal prices and 7% discount rate.

### **Equity Research**

Leaving all else unchanged, we maintain our BUY rating and lift our C\$0.60/sh PT to C\$0.70/sh based on 0.5xNAV<sub>7%</sub> of the PEA mine plan at 127c/lb Zn, 104c/lb Pb and US\$24/oz, net of option payments, adding resources outside the mine plan at 120c/oz AgEq.

	BNKR	5	CP			BNKR	5	СР	
Bunker Hill (100%)	Sept PEA	Old	New	∆ to old	Bunker Hill (100%)	Sept PEA	Old	New	Δ to
UG inventory (Mt )	5.8	5.0	5.8	17%	UG mining cost (US\$/t)^	41.0	61.6	41.4	-33
Grade (% Zn)	5.0%	5.5%	5.0%	-9%	Processing cost (US\$/t)^	15.0	15.5	15.5	0
Grade (% Pb)	2.8%	2.9%	2.8%	-4%	G&A cost (US\$/t ROM)^	6.0	6.2	6.2	0
Grade (g/t Ag)	51.4	52.2	50.6	-3%	TC + Transport (US\$/t con)	na	286.8	286.8	0%
Zinc mined (000t Zn)	289	274	291	6%	AISC (US\$/Ib Zn payable)	0.47	0.59	0.36	-38
Lead mined (000t Pb)	162	144	161	12%	AISC (SCP, US\$/Ib ZnEq) <sup>+</sup>	na	0.71	0.61	-14
Silver mined (000oz)	9568	7401	8418	14%	Initial capex (US\$m)	44	42	44	49
LOM avg ROM (Mt pa)	0.5	0.5	0.5	-4%	LOM sust. capex (US\$m)	63	74	63	-14
Zn Recovery (LOM, %)	92%	92%	92%	0%	LOM FCF (US\$M)	278.0	197.9	288.4	46
Prod'n (000t pa ZnEq)	41	42	39	-8%	Discount rate (%)	8.0%	7.0%	7.0%	0%
Mine life (years)	11	10	12	17%	Project NPV (US\$m)	108	128	175	37
Zinc price (US\$000/t)	2,535	2,800	2,800	0%	Asset IRR (%)	35%	49%	52%	79
Lead price (US\$000/t)	1,984	2,000	2,000	0%	Source: 2Q21 PEA, SCPe; *BNk	'R AISC Zn only	, incl. sme	lter costs,	net by-
Silver price (US\$/oz)	20	24	24	0%	product, +SCP AISC ZnEq mine	gate, cash bred	ak even Us	5\$0.61/lb;	^Smal
Zinc Payability (%)	82%	82%	82%	0%	% deltas due to rounding				
					•				

#### Table 2. SCPe old vs new inputs & economics

#### Why we like Bunker Hill

- Ex Barrick operating and leadership team take over from prior promoters •
- 5Mt @ 9% ZnEq provides starter-mine under PEA •
- Reinterpretation of 180km of drilling with 95yrs data digitised to open Ag potential •
- Consolidation opportunities around four operating mills in Silver Valley •

#### Catalysts

- 2H21: Potential re-profiling of EPA payments •
- 2H21: Project financing including debt / offtake / streaming options
- 2H21/CY22: Potential TSX-V listing •
- Year end 2021: Construction decision •
- 2H23: First production

Brock Salier (London) M: +44 7400 666 913 bsalier@sprott.com Justin Chan (London) M: +44 7554 784 688 jchan@sprott.com Brandon Gaspar (Toronto) M: +1 437 533 3142 bgaspar@sprott.com Eleanor Magdzinski (Toronto) M: +1 705 669 7456 emagdzinski@sprott.com

## **Equity Research**

20 September 2021

Ticker: BNKR CN Author: B Salier / B Gaspar								Country: USA, Idaho Asset: Bunker Hill Mine			
Commodity price	CY21E	CY22E	CY23E	CY24E	CY25E	Resource/Inventory	Mt	Zn %		Mt	Zn %
Zn price (US\$/t)	1.27	1.27	1.27	1.27	1.27	0.2766	4Q20	) MRE		SCP inv	entory
Pb price (US\$/t)	0.91	0.91	0.91	0.91	0.91	Indicated	4.0	5.52%		5.8	, 5.03%
Ag price (US\$/oz)	24.0	24.0	24.0	24.0	24.0	Inferred	5.1	4.88%			
SOTP <i>project</i> valuation*		US\$m	o/ship	NAVx	C\$/sh	Total	9.1	5.16%	Total	5.8	5.0%
Bunker Hill NPV (build start 40	)22)	175	100%		0.38	Funding: uses			Funding: sour		
Option / EPA payments	. ,	(22)	100%	0.50x	(0.05)	Mine build capex (US\$m)	43.8		Cash+ITM optio		45.0
Resor. ex rsv @ 5% (120c/oz A	AgEa)	28	100%	1.00x	0.12	SCPe pre-prod'n expl'n	12.1		SCPe debt @ 6		28.4
Net cash 2Q21	0 1	2.4	100%	1.0x	0.01	SCPe work cap(US\$m)	5.4		SCPe DFS equ		6.0
Cash from ITM options		53.2	100%	1.0x	0.23	SCPe G&A+fin cost (US\$m)	8.1			ces (US\$m)	79.4
NAV @ 4Q22		237	292.1		0.70	Total uses: group (US\$m)	69			Buffer	C\$10r
*Build start, ex fin. cost + G&A,	dil. for opti			AV todav:		Share data (m)	Basic	FD	FF FD	_ = = = = = = = = = = = = = = = = = = =	
Sensitivities to discount and a				,		Shares (m)	163.7	283.79	319		
Group NAV (US\$m)	-		1.27/lb		1 50/lb	Ratio analysis	CY20E	CY21E	CY22E	CY23E	CY24
9.0% discount	168	192	217	241	276	Shares out (m)	114.3	163.7	163.7	163.7	163.7
7.0% discount	185	211	238	264	302	EPS (Cc/sh)	22.6	0.1	-	4.3	14.9
5.0% discount	206	234	263	292	332	CFPS before w/c (C\$/sh)	-	-	_	4.5	2.4
Price target (C\$/sh)	1.08/lb			1.37/lb		EV (C\$m)	65.1	39.6	43.3	72.0	60.6
9.0% discount	0.54	0.59	0.65	0.71	0.79	FCF vield (%)	-	- 39.0	45.5	, 2.5	33%
7.0% discount	0.54	0.59	0.05	0.76	0.79	Income statement	CY20E	CY21E	CY22E	CY23E	CY24
5.0% discount	0.62	0.68	0.75	0.70	0.94	Revenue (US\$m)	-	CIZIE	-	23.3	69.3
*Project level NPV, excl finance						COGS (US\$m)	-	-	*	13.4	38.9
Group valuation over time^	3Q21	3Q22	3Q23	3Q24	3Q25	Gross profit (US\$m)	-	-	-	9.9	30.3
						• • • •					
Project NPV (US\$m)	159	172	212	229	222	G&A (US\$m)	2.1	3.3	2.0	2.0	2.4
Centra G&A/fin. cost (US\$m)	(32)	(23)	(22)	(18) (77.0)	(15)	Exploration (US\$m)	13.0 1.6	11.2	4.0	- 1.7	- 2.1
Net cash prior qtr (US\$m)	2.4	(2.1)	(19.9)	(27.0)	(11)	Finance costs (US\$m)	1.0	0.1	-	1.7	
Cash from ITM options	53.2	53.2	53.2	53.2	53.2	Tax (US\$m)				-	1.7
Option / EPA payments	(22)	(22)	(22)	(22)	(22)	Other (US\$m)	(37.6)	(14.7)	0.5	0.5	4.4
NAV (US\$m)	161	178	202	215	228	Net income (US\$m)	20.9	0.1	(6.5)	5.7	19.8
FD share count (m)	284	284	319	319	319	Cash flow statement	CY20E	CY21E	CY22E	CY23E	CY24
1xNAV7%/sh FF FD (US\$/sh)	0.57	0.63	0.63	0.67	0.71	EBITDA (US\$m)	(15.7)	(15.6)	(6.5)	7.4	27.4
1xNAV/sh over time (US\$, ge						Add share based (US\$m)	2.3	1.1	0.5	0.5	0.5
1xNAV (US\$/sh)	1.08/lb	_		1.37/lb		Net change wkg cap (US\$m)	7.7	(1.8)	-	-	8.2
9.0% discount	0.45	0.54	0.62	0.71	0.83	Cash flow ops (US\$m)	(21.2)	(12.5)	(6.0)	6.3	15.9
7.0% discount	0.50	0.59	0.68	0.77	0.89	PP&E: build + sust (US\$m)	2.7	0.1	8.7	35.0	4.5
	0.55	0.65	0.74	0.84	0.97	PP&E - expl'n (US\$m)	-	-	-	-	-
5.0% discount			Fully dilute	ed for min	e build	Cash flow inv. (US\$m)	(2.7)	(0.1)	(8.7)	(35.0)	(4.5)
*Diluted for options under PT bu									(11.0)	-	-
*Diluted for options under PT bu SCPe Production	ut not mine CY24	CY25	CY26	CY27	CY28	Share issue (US\$m)	(59.4)	(12.0)	(11.0)		
5.0% discount *Diluted for options under PT but SCPe Production Production (000kt ZnEq)			<b>CY26</b> 41.8	<b>CY27</b> 35.5	CY28 37.1	Share issue (US\$m) Debt draw (repay) (US\$m)	-	(12.0) -	(28.4)	-	7.1
*Diluted for options under PT bu SCPe Production	CY24	CY25						(12.0) - <b>11.9</b>		-	
*Diluted for options under PT bu SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^	<b>CY24</b> 30.3	<b>CY25</b> 39.8	41.8	35.5	37.1 0.64 0.64	Debt draw (repay) (US\$m)	-	- <b>11.9</b> (0.7)	(28.4)	-	<b>(7.1</b> ) 4.3
*Diluted for options under PT bu SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^	CY24 30.3 0.73	CY25 39.8 0.70	41.8 0.69	35.5 0.79	37.1 0.64	Debt draw (repay) (US\$m) Cash flow fin. (US\$m)	- 58.3	- 11.9	(28.4) <b>39.4</b>	-	<b>(7.1</b> ) 4.3
*Diluted for options under PT bu SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq)	CY24 30.3 0.73 0.65	CY25 39.8 0.70 0.70	41.8 0.69 0.64	35.5 0.79 0.68	37.1 0.64 0.64	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m)	- <b>58.3</b> 34.4	- <b>11.9</b> (0.7)	(28.4) <b>39.4</b> 24.7	- - (28.7)	<b>(7.1</b> 4.3
*Diluted for options under PT bu SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet	- 58.3 34.4 CY20E	- 11.9 (0.7) CY21E	(28.4) <b>39.4</b> 24.7 <b>CY22E</b>	- (28.7) CY23E	(7.1) 4.3 CY24 3.2
Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t ZnEq)^ AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ tedeductions as cost, net by-proc	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m)	- 58.3 34.4 CY20E 3.6	- 11.9 (0.7) CY21E 2.9	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6	- (28.7) <b>CY23E</b> (1.1)	(7.1) 4.3 CY24 3.2 11.0
Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ AISC SCP (US\$/t AgEq)^ AISC SCP (US\$/t AgEq)^	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41 ions 1.00	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m)	- 58.3 34.4 CY20E 3.6 2.7	- 11.9 (0.7) CY21E 2.9 2.5	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5	- (28.7) <b>CY23E</b> (1.1) 2.5	(7.1) 4.3 CY24 3.2 11.0 44.9
*Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-proof S0kt 40kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4	- 11.9 (0.7) <b>CY21E</b> 2.9 2.5 0.6	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2	(7.1) 4.3 CY24
*Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-proof S0kt 40kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41 ions 1.00	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m) Total assets (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4 6.7	- (0.7) CY21E 2.9 2.5 0.6 5.9	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2 <b>39.3</b>	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2 <b>45.6</b>	(7.1) 4.3 CY24 3.2 11.0 44.9 59.0
*Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-prod S0kt 40kt 30kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41 ions 1.00 0.85	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m) Total assets (US\$m) Debt (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4 6.7 0.1	- (0.7) (0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.7	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2 <b>39.3</b> 28.4	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2 <b>45.6</b> 28.4	(7.1 4.3 CY24 3.2 11.0 44.9 59.0 21.3 3.2
Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-proof S0kt 40kt 20kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41 ions 0.85 0.70 0.55	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m) Total assets (US\$m) Debt (US\$m) Accounts payable (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4 6.7 0.1 2.4	- (0.7) CY21E 2.9 2.5 0.6 5.9 - 3.0	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2 <b>39.3</b> 28.4 3.0	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2 <b>45.6</b> 28.4 3.0	(7.1) 4.3 CY24 3.2 11.0 44.9 59.0 21.3
Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-proof S0kt 40kt 20kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41 ions 1.00 0.85 0.70	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m) Total assets (US\$m) Debt (US\$m) Accounts payable (US\$m) Others (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4 6.7 0.1 2.4 4.0	- 11.9 (0.7) CY21E 2.9 2.5 0.6 5.9 - 3.0 3.3	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2 <b>39.3</b> 28.4 3.0 28.0	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2 <b>45.6</b> 28.4 3.0 (0.7)	(7.1 4.3 CY24 3.2 11.0 44.9 59.0 21.3 3.2 12.1 49.2
Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-proof S0kt 40kt 20kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 3.8 9.41 ions 0.85 0.70 0.55	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m) Total assets (US\$m) Debt (US\$m) Accounts payable (US\$m) Others (US\$m) Total liabilities (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4 6.7 0.1 2.4 4.0 38.2	- 11.9 (0.7) CY21E 2.9 2.5 0.6 5.9 - 3.0 3.3 3.3	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2 <b>39.3</b> 28.4 3.0 28.0 56.1	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2 <b>45.6</b> 28.4 3.0 (0.7) 56.1	(7.1) 4.3 CY24 3.2 11.0 44.9 59.0 21.3 3.2 12.1
*Diluted for options under PT but SCPe Production Production (000kt ZnEq) AISC BNKR (US\$/t Zn)* AISC SCP (US\$/t ZnEq)^ Production (000kt AgEq) AISC SCP (US\$/t AgEq)^ *deductions as cost, net by-prod S0kt 40kt 30kt 20kt 10kt	CY24 30.3 0.73 0.65 3.1 9.35	CY25 39.8 0.70 0.70 4.1 10.61 tosts to m	41.8 0.69 0.64 4.3 9.29	35.5 0.79 0.68 3.6 9.97	37.1 0.64 0.64 9.41 ions 0.85 0.70 0.55 0.40	Debt draw (repay) (US\$m) Cash flow fin. (US\$m) Net change in cash (US\$m) Balance sheet Cash (US\$m) Acc rec. + invet. (US\$m) PP&E & expl'n (US\$m) Total assets (US\$m) Debt (US\$m) Accounts payable (US\$m) Others (US\$m) Total liabilities (US\$m) Shareholders' equity (US\$m)	- 58.3 34.4 CY20E 3.6 2.7 0.4 6.7 0.1 2.4 4.0 38.2 0.0	- 11.9 (0.7) CY21E 2.9 2.5 0.6 5.9 - 3.0 3.3 27.7 6.3	(28.4) <b>39.4</b> 24.7 <b>CY22E</b> 27.6 2.5 9.2 <b>39.3</b> 28.4 3.0 28.0 56.1 17.8	- (28.7) <b>CY23E</b> (1.1) 2.5 44.2 <b>45.6</b> 28.4 3.0 (0.7) 56.1 18.3	(7.1 4.3 CY24 3.2 11.0 44.9 <b>59.0</b> 21.3 3.2 12.1 49.2 18.8

Source: SCP estimates



#### DISCLOSURES & DISCLAIMERS

This research report (as defined in IIROC Rule 3400) is issued and approved for distribution in Canada by Sprott Capital Partners LP ("SCP"), an investment dealer who is a member of the Investment Industry Regulatory Organization of Canada ("IIROC") and the Canadian Investor Protection Fund ("CIPF"). The general partner of SCP is Sprott Capital Partners GP Inc. and SCP is a wholly-owned subsidiary of Sprott Inc., which is a publicly listed company on the Toronto Stock Exchange under the symbol "SII". Sprott Asset Management LP ("SAM"), a registered investment manager to the Sprott Funds and is an affiliate of SCP. This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP and/or affiliated companies or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

**DISSEMINATION OF RESEARCH:** SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a pre-determined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact <u>unsubscribe@sprott.com</u> and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

**RESEARCH ANALYST CERTIFICATION:** Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

**UK RESIDENTS:** Sprott Partners UK Limited ("Sprott") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to b uy or sell any security. Sprott and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by Sprott's clients as part of their advisory services to them or is short term market commentary. Neither Sprott nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

**IMPORTANT DISCLOSURES FOR U.S. PERSONS:** This research report was prepared by Sprott Capital Partners LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.



### **Equity Research**

**ANALYST CERTIFICATION / REGULATION AC:** The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

SPROTT CAPITAL PARTNERS EXPLANATION OF RECCOMENDATIONS: Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

BUY: The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

NEUTRAL: The stock's total returns are expected to be in line with the overall market

SELL: The stocks total returns are expected to be materially lower than the overall market

TENDER: The analyst recommends tendering shares to a formal tender offering

**UNDER REVIEW:** The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a reevaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

**NOT RATED ((N/R):** The stock is not currently rated

Research Disclosure					
1	SCP and its affiliates collectively beneficially owns 1% or more of any class of the issuer's equity securities <sup>1</sup>	NO			
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	NO			
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO			
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	YES			
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO			
6	SCP is making a market in an equity or equity related security of the issuer	NO			
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO			
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	NO			
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO			

Sprott Capital Partners Equity Research Ratings:

Summary of Recommendations as of September 2021				
BUY:	46			
HOLD:	0			
SELL:	0			
UNDER REVIEW:				
TENDER:	0			
NOT RATED:	0			
TOTAL	46			

<sup>&</sup>lt;sup>1</sup> As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month

